West Nile virus (WNV) infection was first recognized in the United States in 1999 and is known to be a potentially lethal disease. 1 Humans are infected by mosquitoes, but the virus can also be transmitted through organ transplantation and blood transfusions. 2 Disease presentation in humans ranges from a mild, self-limited influenza-like picture to severe neurological illnesses.
Risk factors for severe disease are older age, and possibly immunosuppression. 3 We describe three BMT patients with WNV infection, demonstrating the variable disease manifestations. All three patients were seen in summer 2003 during a WNV outbreak in Colorado. None of the patients had recently received blood products, suggesting mosquito bites in the community as the most likely source of infection.
The first case is a 46-year-old woman 2 years postnonmyeloablative stem cell transplant (NST) from an URD for NHL. Post transplant complications included chronic cutaneous and intestinal GVHD and pulmonary aspergillosis. Her immunosuppressive regimen consisted of azathioprine, mycophenolate, and steroids. She was admitted with 2 days of fever, nausea, vomiting, confusion, and fatigue. She was febrile, ill-appearing, with lethargy and diffuse weakness, but without meningismus or rash. There was no recent travel, outdoor activities, or sick contacts. She had normal lab values.
Despite antibiotics, her mental status and weakness worsened. Her CSF was clear with normal opening pressure, pleocytosis of 19 cells/ml (neutrophil predominant), high protein (81 mg/dl), normal glucose, negative Gram stain and bacterial, viral, and fungal cultures, and negative cytology. Within 5 days, she became unresponsive with diffuse flaccid paralysis, requiring intubation. An MRI showed patchy hyperintensity of both thalami and cerebral peduncles. Serum and CSF WNV IgM returned positive. The patient was enrolled in a doubleblinded study of IVIG vs placebo. She remained in a profound coma, with diffuse slowing in her EEG. Supportive care was withdrawn. Autopsy revealed widespread multifocal areas of necrosis, consistent with WNV meningoencephalitis.
The second case is a 41-year-old woman who received an MSD BMT for relapsed AML 2 years prior. She developed mild skin and intestinal GVHD, which resolved and remained quiescent off of immunosuppression. She presented with several weeks of fever and myalgias and several days of nausea, anorexia, and fatigue. Physical examination was unremarkable. She denied any recent travel, sick contacts, or outdoor activities. Laboratory values were normal. After 2 days, serum WNV serologies (IgM, IgG) returned positive. Gradually, her symptoms resolved without any sequelae.
The third case is a 62-year-old woman, who received an MSD NST for AML 9 months earlier. She was on prednisone and tacrolimus for intestinal GVHD when she was admitted after collapsing at home. She complained of fatigue and generalized weakness for several days, worsened by positional vertigo and blurry vision. She denied any recent outdoor activities, mosquito bites, or travel. The patient was febrile and in distress after any rapid movement, but comfortable when lying supine. Neurologic examination showed mental slowing and symmetric weakness in her limbs without meningismus or focal deficits. Laboratory values were unremarkable. Her CSF was clear with normal opening pressure, pleocytosis of 43 cells/ml (mononuclear predominant), high protein (75 mg/dl), normal glucose, negative Gram stain, bacterial and viral cultures, and cytology. MRI was normal. Serum and CSF WNV IgM were positive, whereas serum and CSF WNV IgG were normal. Her visual complaints were diagnosed as chorioretinitis secondary to WNV. She was enrolled in a double-blinded study with IVIG vs placebo. She had prompt recovery of her mental status and was discharged. She is currently asymptomatic.
During WNV epidemics, a high index of suspicion for this illness is required when evaluating a febrile immunosuppressed patient. To date, there have been four other case reports of WNV encephalitis in BMT patients, all of whom, similar to our three patients, presented with fever without meningismus or rash. [4] [5] [6] Interestingly, both Reddy et al and Hong et al described focal neurologic deficits in two patients who presented with fever and asymmetric upper extremity weakness. Hong et al also described febrile seizures in one of his patients, which are considered an unusual presentation for WNV encephalitis. All four cases progressed rapidly to unresponsiveness and had fatal outcomes. Only one of our patients progressed to coma and death. We suspect that immunosuppressive therapy plays a significant role in disease severity. Among our cases, the patient requiring no immunosuppressive therapy at the time of diagnosis experienced only mild symptoms and did not require hospitalization.
WNV diagnosis is based on the presence of WNV antibodies in the serum or CSF. Within the first 4 days of symptoms, WNV IgM antibody can be found in the serum or CSF in 75% of patients, whereas it is positive in almost all patients at 1 week. 3 This antibody response can persist for many months. In areas where WNV is endemic, diagnosis requires a four-fold increase in serum titers between acute and convalescent phases of illness. 7 We did not encounter problems with false-negative WNV serologies, which may occur, especially in immunosuppressed patients. Under these circumstances, diagnosis may require positive serum and/or CSF WNV RT-PCR. This test is commonly positive early in the course of encephalitis, and becomes negative shortly thereafter. In most patients, the WNV PCR is already negative by the time symptoms occur, but should still be checked if serologies are negative and suspicion is high. 8 The standard of care for WNV-infected patients is supportive therapy. There has yet to be a drug with proven clinical efficacy. Treatment with high-titer anti-WNV immunoglobulin seems promising 9, 10 and large, randomized, placebo-controlled studies are in progress.
Preventative measures must be undertaken, especially during large outbreaks, such as early season larviciding and active surveillance of the virus in animals and humans. Since the virus can also be transmitted via blood products, WNV-screening strategies are under investigation. It is also critical that BMT patients be educated on ways to reduce their risk of mosquito bites. Patients should be informed about the use of mosquito repellants containing N,Ndiethyl-meta-toluamide (DEET), staying indoors during dawn and dusk, and reducing vegetation typically infested by mosquitoes around their homes. 
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